Cambridge, United Kingdom
CS Genetics is a UK-based company founded in 2014, operating within the Biotechnology, Health Care, and Life Sciences industries. The company has pioneered a disruptive platform for single-cell genomics that eschews traditional instruments in favor of a solution-phase chemical biology approach. This platform promises to democratize the application of single-cell technology, thereby empowering researchers to pursue more ambitious scientific inquiries.
The key advantage of CS Genetics' platform lies in its ease-of-use, scalability, and affordability, which could significantly broaden its adoption across scientific fields. This innovation positions the company as a potential game-changer in genomics research.
In terms of financing, CS Genetics secured a $2.20M Debt Financing investment as of 01 June 2021. The absence of specified investors from this round may suggest a range of institutional interest or other financing sources.
)
)
